|
|
Line 16: |
Line 16: |
|
| |
|
| =Suggested studies to add to this page= | | =Suggested studies to add to this page= |
| | |
| | |
| | ===2021: [https://academic.oup.com/ntr/advance-article/doi/10.1093/ntr/ntab004/6073671?fbclid=IwAR3PlyqgttsQh0MO7f6T8EYcGXt6Rd5GXF303SFe-hPQpsGl_wzaho04djs Impact of Tobacco Smoking on the risk of COVID-19.A large scale retrospective cohort study]=== |
| | |
| | |
|
| |
|
| =Threads about COVID on Twitter by @phil_w888= | | =Threads about COVID on Twitter by @phil_w888= |
| ==[https://twitter.com/phil_w888/status/1251956936947331072 So far all existing data show smokers are underrepresented in Covid19 hospitalization data]== | | |
| | |
| | ===[https://twitter.com/phil_w888/status/1251956936947331072 So far all existing data show smokers are underrepresented in Covid19 hospitalization data]=== |
| *[https://threadreaderapp.com/thread/1251956936947331072.html Above thread on threadreader app] | | *[https://threadreaderapp.com/thread/1251956936947331072.html Above thread on threadreader app] |
| ==[https://twitter.com/phil_w888/status/1279973073811197952 The results of preprints & peer-reviewed studies describing the relationship between smoking and SARS-CoV-2/COVID-19 are reported in this thread]== | | |
| | |
| | ===[https://twitter.com/phil_w888/status/1279973073811197952 The results of preprints & peer-reviewed studies describing the relationship between smoking and SARS-CoV-2/COVID-19 are reported in this thread]=== |
| *[https://threadreaderapp.com/thread/1279973073811197952.html Above thread on threadreader app] | | *[https://threadreaderapp.com/thread/1279973073811197952.html Above thread on threadreader app] |
| ==[https://twitter.com/phil_w888/status/1282094429398921216 A compilation of preprints, peer-reviewed studies, and datasets documenting SARS-CoV-2/Covid-19 patients' smoking status - only the ones with at least 1000 patients.]== | | |
| ==[https://twitter.com/phil_w888/status/1282814318782771200 Studies of SARS-CoV-2/Covid-19 patients in which vaping is mentioned]== | | |
| | ===[https://twitter.com/phil_w888/status/1282094429398921216 A compilation of preprints, peer-reviewed studies, and datasets documenting SARS-CoV-2/Covid-19 patients' smoking status - only the ones with at least 1000 patients.]=== |
| | *Thread on twitter |
| | |
| | |
| | ===[https://twitter.com/phil_w888/status/1282814318782771200 Studies of SARS-CoV-2/Covid-19 patients in which vaping is mentioned]=== |
| | *Thread on twitter |
| | |
|
| |
|
|
| |
|
| =Nicotine Replacement Therapy (NRT)= | | =Nicotine Replacement Therapy (NRT)= |
|
| |
|
| ==2020: Nicotine-replacement therapy, as a surrogate of smoking, and the risk of hospitalization with Covid-19 and all-cause mortality: a nationwide, observational cohort study in France== | | |
| | ===2020: Nicotine-replacement therapy, as a surrogate of smoking, and the risk of hospitalization with Covid-19 and all-cause mortality: a nationwide, observational cohort study in France=== |
| From February 15, 2020 to June 7, 2020, hospitalization with Covid-19 occurred in 647 patients (151 patients in the nicotine-replacement therapy group and 496 patients in the unexposed group). | | From February 15, 2020 to June 7, 2020, hospitalization with Covid-19 occurred in 647 patients (151 patients in the nicotine-replacement therapy group and 496 patients in the unexposed group). |
| Results In the first analysis, 297,070 individuals without major smoking-related diseases exposed to nicotine-replacement therapy were matched with 558,228 unexposed individuals without major smoking-related diseases. | | Results In the first analysis, 297,070 individuals without major smoking-related diseases exposed to nicotine-replacement therapy were matched with 558,228 unexposed individuals without major smoking-related diseases. |
| In the main multivariable analysis, nicotine-replacement therapy was associated with a decreased risk of hospitalization with Covid-19 compared with unexposed individuals. | | In the main multivariable analysis, nicotine-replacement therapy was associated with a decreased risk of hospitalization with Covid-19 compared with unexposed individuals. |
| Nicotine-replacement therapy exposure was also associated with a decreased risk of intubation or death in hospitalized individuals with Covid-19. (13 vs. 73 patients). | | Nicotine-replacement therapy exposure was also associated with a decreased risk of intubation or death in hospitalized individuals with Covid-19. (13 vs. 73 patients). |
| | |
| | |
|
| |
|
| =Smoking= | | =Smoking= |
|
| |
|
| ==2020: How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection?== | | |
| | ===2020: How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection?=== |
| COVID-19 positive patients who smoke are more often asymptomatic or exhibit less severe respiratory symptoms than non-smokers. | | COVID-19 positive patients who smoke are more often asymptomatic or exhibit less severe respiratory symptoms than non-smokers. |
| The macrophages, which are directly infected by the SARS-CoV-2 virus, may drive the cytokine storm in the lings. | | The macrophages, which are directly infected by the SARS-CoV-2 virus, may drive the cytokine storm in the lings. |
Line 42: |
Line 62: |
| The nicotine use may lessen or eliminate ARDS in the smoking COVID -19 patients. | | The nicotine use may lessen or eliminate ARDS in the smoking COVID -19 patients. |
|
| |
|
| ==2020: Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory–confirmed COVID-19 cases== | | |
| | ===2020: Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory–confirmed COVID-19 cases=== |
| COVID-19 patients were disproportionately older, males and with increased prevalence of one or more comorbidities, particularly diabetes, obesity, and hypertension. | | COVID-19 patients were disproportionately older, males and with increased prevalence of one or more comorbidities, particularly diabetes, obesity, and hypertension. |
| Current smokers were 23% less likely to be diagnosed with COVID-19 compared to non-smokers. | | Current smokers were 23% less likely to be diagnosed with COVID-19 compared to non-smokers. |
| | |
| | |
|
| |
|
| =Smokeless Tobacco= | | =Smokeless Tobacco= |
| | |
|
| |
|
|
| |
|
| =Vapor Technology= | | =Vapor Technology= |
| | |
|
| |
|
|
| |
|